Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia

References

• Chiorazzi N, Rai K R, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 325: 804–815
   Web of Science ®Google Scholar
• Rozman C, Montserrat E. Chronic lymphocytic leukemia. New Engl J Med 1995; 333: 1052–1057
   PubMed Web of Science ®Google Scholar
• Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French cooperative group on chronic lymphocytic leukemia. N Engl J Med 1998; 338: 1506–1514
   PubMed Web of Science ®Google Scholar
• Keating M J, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Rai K R, Peterson B L, Appelbaum F R, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757
   PubMed Web of Science ®Google Scholar
• Sorensen J M, Vena D A, Fallavollita A, Chun H G, Cheson B D. Treatment of refractary chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow up report. J Clin Oncol 1997; 15: 458–465
   PubMed Web of Science ®Google Scholar
• O'Brien S M, Kantarjian H, Cortes J, Beran M, Koller C A, Giles F J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414–1420
   PubMed Web of Science ®Google Scholar
• Bosch F, Ferrer A, López-Guillermo A, Giné E, Bellosillo B, Villamor N, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol 2002; 119: 976–984
   PubMed Web of Science ®Google Scholar
• Eichhorst B F, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–891
   PubMed Web of Science ®Google Scholar
• Gowda A, Byrd J C. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol 2006; 13: 266–272
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Orchard J A, Ibbotson R E, Davis Z, Thomas P W, Stevenson F K, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023–1029
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, et al. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Begleiter A, Goldenberg G J, Anhalt C D, Lee K, Mowat M RA, Israels L G, et al. Mechanisms of resistance to chlorambucil in chronic lymphocytic leukemia. Leuk Res 1991; 15: 1019–1027
   PubMed Web of Science ®Google Scholar
• Chun H G, Leyland-Jones B, Cheson B D. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991; 9: 175–188
   PubMed Web of Science ®Google Scholar
• Liliemark J, Juliusson G. On the pharmacokinetics of the 2-chloro-2'-deoxyadenosine in humans. Cancer Res 1991; 51: 5570–5572
   PubMed Web of Science ®Google Scholar
• Montserrat E. Developing risk-adapted treatment strategies for chronic lymphocytic leukemia. Chronic lymphoid leukemias, B D Cheson. Marcel Dekker Inc, New York. 2001; 377–391
   Google Scholar
• Kern D H, Weisenthal L M. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990; 82: 582–588
   PubMed Web of Science ®Google Scholar
• Bosanquet A G. Correlations between therapeutic response of leukaemias and in vitro drug-sensitivity assay. Lancet 1991; 337: 711–714
   PubMed Web of Science ®Google Scholar
• Morabito F, Stelitano C, Callea I, Filangeri M, Oliva B, Sculli G, et al. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Haematologica 1996; 81: 224–231
   PubMed Web of Science ®Google Scholar
• Bosanquet A G, Copplestone J A, Johnson S AN, Smith A G, Povey S J, Orchard J A, et al. Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay. Br J Haematol 1999; 106: 474–476
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994; 330: 319–322
   PubMed Web of Science ®Google Scholar
• Silber R, Degar B, Costin D, Newcomb E W, Mani M, Rosenberg C R, et al. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine and captothecin analogs. Blood 1994; 84: 3440–3446
   PubMed Web of Science ®Google Scholar
• Bosanquet A G, Johnson S AN, Richards S M. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Br J Haematol 1999; 106: 71–77
   PubMed Web of Science ®Google Scholar
• Morabito F, Callea I, Console G, Stelitano C, Sculli G, Filangeri M, et al. The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia. Haematologica 1997; 82: 560–565
   PubMed Web of Science ®Google Scholar
• Callea I, Console G, Sculli G, Filangri M, Messina G, Morabito F. Chlorambucil synergizes with purine analogs in inducing in vitro cytotoxicity in B-cell chronic lymphocytic leukemia. Haematologica 1998; 83: 756–757
   PubMed Web of Science ®Google Scholar
• Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclofosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 2836–2843
   PubMed Web of Science ®Google Scholar
• Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62: 567–575
   PubMed Web of Science ®Google Scholar
• Molica S, Levato D, Cascavilla N, Levato L, Musto P. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and β2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 1999; 62: 117–122
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Zhong Y, Bakke A C, Fan G, Braziel R M, Gatter K M, Leis J F, et al. Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay. Cytometry B Clin Cytom 2007; 72: 189–195
   PubMed Web of Science ®Google Scholar
• Fegan C, Robinson H, Thompson P, Whittaker J A, White D. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995; 9: 2003–2008
   PubMed Web of Science ®Google Scholar
• Callea V, Stelitano C, Callea I, Console G, Brugiatelli M, Morabito F. In vitro drug-induced cytotoxicity predicts clinical response to high-dose chlorambucil in B-cell chronic lymphocytic leukemia. Haematologica 1999; 84: 863–864
   PubMed Web of Science ®Google Scholar
• Hilgenfeld E, Knauf W U, Thiel E. Cytotoxicity of flurarabine in vitro cannot predict clinical outcome in patients with advanced stage B-cell chronic lymphocytic leukemia (B-CLL). Leukemia 1995; 9: 541–546
   Google Scholar
• Gottardi D, De Leo A M, Alfarano A, Stacchini P, Circosta P, Gregoretti M G, et al. Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations. Br J Haematol 1997; 99: 147–157
   PubMed Web of Science ®Google Scholar
• Bromidge T J, Turner D L, Howe D J, Johnson S A, Rule S AJ. In vitro chemosensitivity of chronic lymphocytic leukemia to purine analogues-correlation with clinical course. Leukemia 1998; 12: 1230–1235
   PubMed Web of Science ®Google Scholar
• Morabito F, Stelitano C, Callea I, Dattola A, Console G, Puci G, et al. In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukemia. Br J Haematol 1998; 102: 528–531
   PubMed Web of Science ®Google Scholar